Table 4.
Hazard ratio [95% confidence interval] for cardiovascular mortality based on presence or absence of echocardiographic abnormalities in patients with PVCs during recovery, n = 1327 (138 events).
| Univariable analysis | Multivariable analysisa | Wald | p | |
|---|---|---|---|---|
| Increased E/e′ ratio | 3.7 [2.6–5.3] | 2.0 [1.4–3.0] | 3.5 | < 0.01 |
| LV dilatation | 3.6 [2.3–5.6] | 2.2 [1.2–3.8] | 2.6 | 0.01 |
| Increased LV mass | 2.6 [1.8–3.6] | 1.7 [1.1–2.5] | 2.6 | 0.01 |
| Reduced LVEF | 3.3 [2.2–4.8] | 1.5 [1.0–2.5] | 1.8 | 0.07 |
| Increased RV/RA gradient | 3.4 [2.2–5.3] | 1.4 [0.9–2.6] | 1.8 | 0.08 |
| Moderate/severe aortic regurgitation | 2.4 [1.4–4.4] | 1.4 [0.8–2.6] | 1.1 | 0.27 |
| Moderate/severe mitral regurgitation | 2.6 [1.7–3.8] | 1.1 [0.7–1.9] | 0.6 | 0.52 |
| Increased LA diameter | 2.6 [1.8–3.6] | 1.0 [0.7–1.5] | 0.0 | 0.98 |
| Moderate/severe tricuspid regurgitation | 1.7 [1.1–2.7] | 0.9 [0.5–1.5] | − 1.2 | 0.22 |
| Moderate/severe aortic stenosis | 1.1 [0.5–2.4] | 0.6 [0.3–1.4] | − 1.1 | 0.29 |
LA left atrial, LV left ventricle/ventricular, LVEF LV ejection fraction.
aHypertension, diabetes, ischemic heart disease, heart failure, body-mass index, use of either betablocker, angiotension-converting enzyme inhibitor, angiotension II blockers, loop diuretics, antihrombotics, anti-coagulants, or calcium channel blockers.